Mumbai, Oct. 29 -- The approved ANDA is therapeutically equivalent to the reference listed drug Brilinta Tablets, 60 mg, of AstraZeneca Pharmaceuticals LP. Ticagrelor is indicated to reduce the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of MI, and to reduce the risk of stent thrombosis in patients treated for ACS. It is also used to lower the risk of a first MI or stroke in high-risk coronary artery disease (CAD) patients and to reduce stroke risk in patients with acute ischemic stroke or high-risk transient ischemic attack (TIA).

The Ticagrelor 60 mg market in the US is estimated at US$236 million for the 12 months ending June 2025, according to IQVIA. Alem...